AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01791868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Trial: NCT03403504
Drug: OXYCONTIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered OXYCONTIN® Tablet 10 mg
Trial: NCT00540722
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04224740
Drug: Standard of care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
Trial: NCT01355068
Drug: Epanutin Infatabs (Phenytoin)
RxNorm normalized name: phenytoin sodium Oral Capsule [Epanutin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable Tablet, 50 mg, Single dose
Trial: NCT01724736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Trial: NCT01724736
Drug: NM504:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
Trial: NCT02110810
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository of 100 mg immediately afterwards while still under sedation
Trial: NCT03712163
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02015598
Drug: Carbocysteine
RxNorm normalized name: Carbocysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
Trial: NCT00256867
Drug: GSK523338
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00701740
Drug: oral isotretinoin and Mexoryl SX / XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, 3/week,continuously for three months
Trial: NCT00701740
Drug: Mexoryl XL / SX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 subjects used only the same moisturizer and SPF 60 sunscreen
Trial: NCT04020510
Drug: onaBoNT-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
Trial: NCT03088293
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
Trial: NCT04307147
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
Trial: NCT00670202
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
Trial: NCT02944799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of alendronate treatment
Trial: NCT02944799
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary supplement of 800mg calcium
Trial: NCT00998309
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax SR 2g, taking once for treatment.
Trial: NCT02959710
Drug: AC-1202 mixed in Ensure®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
Trial: NCT04030715
Drug: bismuth-containing quadral therapy based on antibiotic susceptibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the different mucosal pathology graded by New Sydney System
Trial: NCT01869985
Drug: HCP1104 / Mulex Tab. and Airtal Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCP1104 / Eperisone plus Aceclofenac
Trial: NCT01173627
Drug: Test fentanyl citrate 400 mcg troche
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
Trial: NCT02429427
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
Trial: NCT01307111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Trial: NCT02467478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily for 12 weeks
Trial: NCT00258128
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT00258128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for salslate, used only in the third trial
Trial: NCT00931788
Drug: Antihypertensive agents and lipid lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
Trial: NCT00380354
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02431975
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices.
Trial: NCT01061268
Drug: No topical artificial tear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 patients randomized to not using a topical artificial tear.
Trial: NCT01061268
Drug: Blink® Tears Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blink® Tears Lubricant Eye Drops
Trial: NCT01292226
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to manufacturer recommendation
Trial: NCT04622319
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
Trial: NCT02627846
Drug: Lidocaine with 1:200,000 epinephrine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
Trial: NCT02627846
Drug: Lidocaine with 1:200,000 epinephrine solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
Trial: NCT01101568
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg (single dose) on Days 1 and 10.
Trial: NCT01101568
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10mg (single dose) on Days 3 and 12.
Trial: NCT01101568
Drug: GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1292263 300mg BID Days 6 to 14.
Trial: NCT01207739
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
Trial: NCT01207739
Drug: Clarithromycin and hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
Trial: NCT01207739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
Trial: NCT03445013
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Comparator
Trial: NCT01356602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Trial: NCT00500149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00058578
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02460588
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2
Trial: NCT02460588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Trial: NCT02460588
Drug: Corticosteroid (prednisolone)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive non experimental medication with high dose of corticosteroid.
Trial: NCT01614769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
Trial: NCT02455518
Drug: Hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455518
Drug: Codeine/acetaminophen
RxNorm normalized name: PE/codeine/acetaminophen/cpm ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455518
Drug: Ibuprofen/acetaminophen
RxNorm normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00595699
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02560688
Drug: DS-1040b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg single 12-hour intravenous infusion
Trial: NCT00426985
Drug: Ketoprofen Topical Patch 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02241512
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02241512
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02549690
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
Trial: NCT00313859
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02819648
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
Trial: NCT00109408
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5-20mg po weekly
Trial: NCT00456963
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
Trial: NCT03196505
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Trial: NCT01450930
Drug: Hydrocortisone intramuscular first
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone intramuscular first
Trial: NCT01450930
Drug: Hydrocortisone subcutaneously first
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone subcutaneously first
Trial: NCT02936505
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months.
Trial: NCT02288156
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: via nasal spray
Trial: NCT06522633
Drug: The intervention involves the discontinuation of the opioid.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with dysphagia and esophageal manometry indicating opioid-induced esophageal dysfunction (OIED) will have the opioid discontinued, and esophageal manometry will be repeated.
Trial: NCT02834312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Trial: NCT00830037
Drug: IV Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
Trial: NCT02552355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of matching placebo during a 12 week exercise training program.
Trial: NCT02985125
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
Trial: NCT01070784
Drug: Drug: any available COPD treatment; investigator to decide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
Trial: NCT02805218
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03634605
Drug: Tetracycline Topical Ointment
RxNorm normalized name: tetracycline Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03634605
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00668343
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/ day
Trial: NCT00668343
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg /day
Trial: NCT00902174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to imatinib 100 mg film coated tablets
Trial: NCT01798706
Drug: Antidiabetic background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Trial: NCT01221675
Drug: Antibody TF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preciblage with an antibody
Trial: NCT02949765
Drug: Iron sulfate 105 mg
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily supplementation with iron sulfate 105 mg 1 pill/day
Trial: NCT00471367
Drug: AZD4877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion administered twice a week for 2 weeks
Trial: NCT03273075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
Trial: NCT02372903
Drug: Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
Trial: NCT02824380
Drug: DA-4001 L
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% minoxidil / low dose of finasteride
Trial: NCT01583322
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years.
Trial: NCT03107247
Drug: Imaging Time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to be imaged at an additional time point.
Trial: NCT00850460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills will consist of lactose and will be given one capsule once daily
Trial: NCT03756974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of BX-1, oral solution
Trial: NCT01975935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo sham blinded by encapsulation in the same capsules as the study drug arm
Trial: NCT00657761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution/12h sc for 7 days
Trial: NCT02739594
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
Trial: NCT00540449
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once daily for 96 weeks
Trial: NCT03186404
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03782740
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin capsule
Trial: NCT03782740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Melatonin capsule
Trial: NCT03782740
Drug: Melatonin 20 mg
RxNorm normalized name: melatonin 20 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin capsule
Trial: NCT00601523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
Trial: NCT00206115
Drug: Seroquel Sustained Release (SR)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206115
Drug: Seroquel Immediate Release (IR)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00206115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041546
Drug: Lung lavage with surfactant
FDA approved: no
EMA approved: no
PMDA approved: no